Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?

J Cancer Res Clin Oncol. 2003 Jan;129(1):29-34. doi: 10.1007/s00432-002-0401-y. Epub 2003 Feb 12.

Abstract

Purpose: To elucidate whether hK2 mRNA can be detected in peripheral blood of patients with thyroid disease using reverse transcription polymerase chain reaction (RT-PCR).

Methods: A nested RT-PCR protocol for the detection of hK2 mRNA was established, and blood samples of 72 patients with a history of thyroid cancer, 10 patients with current metastases of thyroid cancer, and 32 volunteers were tested.

Results: hK2-transcripts were significantly more often detected in patients with thyroid cancer (20/72=28%) than in the control group (2/32=6%, P = 0.03, chi-square analysis).

Conclusions: This is the first study reporting on hK2 as a potential molecular marker for patients with thyroid cancer. We could demonstrate a correlation between diagnosis of thyroid cancer and the positive signal for hK2 in the RT-PCR assay. Future studies are necessary to prove the clinical value of hK2 as a molecular marker regarding recurrence and outcome.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Biomarkers, Tumor / genetics
  • Carcinoma, Papillary / blood
  • DNA, Complementary / analysis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Thyroid Neoplasms / blood*
  • Tissue Kallikreins / blood*
  • Tissue Kallikreins / genetics

Substances

  • Biomarkers, Tumor
  • DNA, Complementary
  • Tissue Kallikreins